Medivir AB (publ) (STO:MVIR)

Market Cap	188.44M -43.1%
Revenue (ttm)	3.88M -42.5%
Net Income	-77.82M
EPS	-0.68
Shares Out	448.67M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	656,587
Average Volume	1,106,107
Open	0.4550
Previous Close	0.4520
Day's Range	0.4350 - 0.4550
52-Week Range	0.3400 - 2.8200
Beta	-0.05
RSI	40.81
Earnings Date	Feb 18, 2026

About Medivir AB

Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Sweden, the Nordic region, rest of Europe, and internationally. The company offers Xerclear for the treatment of labial herpes under the Zoviduo name; and Olysio to treat hepatitis C. It also develops Remetinostat, a histone deacetylase (HDAC) inhibitor that has completed Phase II studies for treating mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL), basal cell carcinoma (BCC), and squamous cell carcinoma (SCC); MIV-711...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1987
• Employees: 10
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: MVIR

Financial Performance

In 2024, Medivir AB's revenue was 3.48 million, a decrease of -54.36% compared to the previous year's 7.63 million. Losses were -123.32 million, 38.1% more than in 2023.